Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391499 | 0.93 | HRH3 (0.41) | HRH3CXCR4TSHRALDH1A1HSD17B10 | |
| SCHEMBL4391508 | 0.93 | HRH3 (0.41) | HRH3CXCR4TSHRALDH1A1HSD17B10 | |
| SCHEMBL4394511 | 0.93 | HRH3 (0.41) | HRH3CXCR4TSHRALDH1A1HSD17B10 | |
| SCHEMBL4396981 | 0.91 | HRH3 (0.43) | HRH3CXCR4CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL4388973 | 0.87 | HRH3 (0.44) | HRH3TSHRALDH1A1NPC1 | |
| SCHEMBL4386340 | 0.84 | HRH3 (0.39) | HRH3CXCR4CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL4381878 | 0.84 | HRH3 (0.44) | HRH3TSHRALDH1A1HSD17B10 | |
| SCHEMBL4381873 | 0.84 | HRH3 (0.44) | HRH3TSHRALDH1A1HSD17B10 | |
| SCHEMBL4382192 | 0.84 | HRH3 (0.44) | HRH3TSHRALDH1A1HSD17B10 | |
| SCHEMBL13788003 | 0.81 | HRH3 (0.36) | HRH3CXCR4CYP2D6CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | HRH3 452/4885CXCR4 1707/4885CYP2D6 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.